Benefits
Long-term bone density support
In a 3-year randomized, double-blind, placebo-controlled trial in 244 healthy postmenopausal women, MenaQ7® at 180 mcg/day slowed the age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck compared with placebo. A 3-year placebo-controlled trial is unusually long for a supplement, which makes this the strongest evidence on this page. It was done only in postmenopausal women, so it says nothing about men or younger people. Effects are modest compared with pharmaceutical osteoporosis therapy but reached statistical significance over the multi-year window.
Arterial stiffness and vascular elasticity
In the same 3-year trial of 244 healthy postmenopausal women, MenaQ7® at 180 mcg/day improved carotid-femoral pulse wave velocity and stiffness index versus placebo, along with lower levels of inactive matrix Gla protein. That is real randomized evidence, but it is one trial in one narrow group. When MK-7 was tested directly against artery calcification it did not help: in 68 people with type 2 diabetes and existing heart disease, 360 mcg/day for 6 months missed the main endpoint on CT scanning (P = 0.18) and, on PET imaging, tended toward more active calcification than placebo (P = 0.06).
Activation of vitamin-K-dependent Gla proteins
MenaQ7® consistently lowers circulating inactive osteocalcin and inactive matrix Gla protein, which shows the body is using the vitamin K to switch these proteins on. These are laboratory markers, not health outcomes. The failed 6-month trial in people with diabetes shows why the difference matters: the blood marker improved while the imaging measure of artery calcification did not.
Long half-life and once-daily dosing
MK-7 has a plasma half-life of roughly 3 days versus about 1 hour for MK-4. In a blood-level study in healthy adults, MK-7 accumulated to 7 to 8 times its starting level with continued daily intake and held steadier levels than vitamin K1, so once-daily dosing is practical. This is a blood-level finding only, not evidence of a health benefit.
Original commercial all-trans MK-7
MenaQ7® was the first widely sold all-trans MK-7 and is the exact material used in the published 3-year postmenopausal trial, so a product listing MenaQ7® tells you which form was studied. Other MK-7 brands are not automatically covered by that trial, and being first to market is not itself evidence of a benefit.
Mechanism of action
Gamma-carboxylation of Gla-domain proteins
MK-7 is an essential cofactor for gamma-glutamyl carboxylase, which converts glutamate residues in Gla-domain proteins (osteocalcin, matrix Gla protein, GAS6, Protein S) to gamma-carboxyglutamate, enabling these proteins to bind calcium and perform their physiological functions.
Osteocalcin activation and bone matrix formation
Carboxylated osteocalcin binds hydroxyapatite (bone mineral) and helps incorporate calcium into the bone matrix. Inadequate K2 leaves osteocalcin undercarboxylated and impairs this binding, contributing to age-related bone loss that MK-7 supplementation may help mitigate.
Matrix Gla protein activation and vascular protection
Carboxylated matrix Gla protein is the body's primary inhibitor of vascular calcification, binding calcium ions in vessel walls and limiting calcium phosphate deposition. Low vitamin K leaves MGP inactive, and low activation has been linked with more arterial calcification in observational data. That is an association, not proof, and the one randomized trial that imaged calcification directly found no benefit from MK-7 and a trend in the wrong direction.
Long-chain menaquinone tissue distribution
Compared with shorter menaquinones, MK-7's longer isoprenoid side chain supports efficient incorporation into circulating lipoproteins and extra-hepatic tissue delivery — explaining its disproportionate effect on extra-hepatic Gla proteins like osteocalcin and MGP relative to MK-4.
Clinical trials
Randomized, double-blind, placebo-controlled trial of MenaQ7® MK-7 (180 mcg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: bone mineral density at lumbar spine and femoral neck, osteocalcin carboxylation status. Published in Osteoporosis International.
244 healthy postmenopausal women; 3-year intervention.
MenaQ7® MK-7 significantly improved osteocalcin carboxylation and reduced age-related decline in bone mineral content and bone mineral density at the lumbar spine and femoral neck vs placebo. Effects were modest in magnitude compared with pharmaceutical osteoporosis therapy but reached statistical significance over the 3-year window.
Randomized, double-blind, placebo-controlled trial of MenaQ7® MK-7 (180 mcg/day) vs placebo in 244 healthy postmenopausal women over 3 years. Outcomes: carotid–femoral pulse wave velocity, stiffness index, circulating inactive matrix Gla protein. Published in Thrombosis and Haemostasis.
244 healthy postmenopausal women; 3-year intervention.
Three years of MenaQ7® improved carotid-femoral pulse wave velocity and stiffness index versus placebo, along with significant reductions in inactive matrix Gla protein. This is the same 244-woman trial listed above reported in a second paper, not an independent study. A different randomized trial (68 people with type 2 diabetes and known cardiovascular disease, 360 mcg/day MK-7 for 6 months) did not meet its primary endpoint: no effect on vascular calcification by CT (P = 0.18), and on 18F-NaF PET the MK-7 group tended to increase active calcification versus placebo (P = 0.06). Only the blood marker improved in that trial.
Pharmacokinetic study comparing synthetic vitamin K1 (phylloquinone) and natto-derived MK-7 supplementation in healthy adults to characterize plasma kinetics, half-life, and accumulation. Published in Blood.
Healthy adult volunteers; pharmacokinetic study.
MK-7 demonstrated a very long plasma half-life and far more stable serum levels than phylloquinone, with 7- to 8-fold accumulation during prolonged intake. This supports once-daily dosing. It is a blood-level comparison in healthy volunteers, not a trial of bone, heart or any other health outcome.